Deletion of the Inflammasome Sensor Aim2 Mitigates Aβ Deposition and Microglial Activation but Increases Inflammatory Cytokine Expression in an Alzheimer Disease Mouse Model

NeuroImmunoModulation

Volumn 24, Issue 1, 2017, Pages 29-39

  Wu, Pei Jung ^a   Hung, Yun Fen ^a,b   Liu, Hsin Yu ^a   Hsueh, Yi Ping ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Aim2; Alzheimer disease; Inflammasome; Interleukin 1; Interleukin 18; Interleukin 6; Microglial activation; Neurodegenerative disorder

Indexed keywords

AIM2 INFLAMMASOME; AMYLOID BETA PROTEIN; CRYOPYRIN; CYTOKINE; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; AIM2 PROTEIN, MOUSE; AMYLOID PRECURSOR PROTEIN; CALCIUM BINDING PROTEIN; DNA BINDING PROTEIN; PRESENILIN 1;

5XFAD MOUSE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BARNES MAZE TEST; BEHAVIOR; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE INACTIVATION; HIPPOCAMPUS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MEMORY; MICROGLIA; MOUSE; MOUSE MODEL; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPATIAL MEMORY; Y-MAZE TEST; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; MAZE TEST; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; TIME FACTOR; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CALCIUM-BINDING PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MICROGLIA; MUTATION; PRESENILIN-1; TIME FACTORS;

EID: 85021172035     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000477092     Document Type: Article

References (41)

1. Dickson DW, et al. Alzheimer's disease: A double-labeling immunohistochemical study of senile plaques. Am J Pathol 1988;132:86-101.
2. Mattiace LA, et al. Microglia in cerebellar plaques in Alzheimer's disease. Acta Neuropathol 1990;80:493-498.
3. Rozemuller JM, Eikelenboom P, Stam FC: Role of microglia in plaque formation in senile dementia of the Alzheimer type: An immunohistochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol 1986;51:247-254.
4. Cagnin A, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358:461-467.
5. Dandrea MR, et al. Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer's disease. Biotech Histochem 2001;76:97-106.
6. Fillit H, et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991;129:318-320.
7. McGeer PL, McGeer EG: Inflammation of the brain in Alzheimer's disease: Implications for therapy. J Leukoc Biol 1999;65:409-415.
8. Heneka MT, Kummer MP, Latz E: Innate immune activation in neurodegenerative disease. Nat Rev Immunol 2014;14:463-477.
9. Chiang K, Koo EH: Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol 2014;54:381-405.
10. Fu AK, et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci USA 2016;113:E2705-E2713.
11. Gu Y, et al. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 1997;275:206-209.
12. Kuida K, et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995;267:2000-2003.
13. Tsutsui H, et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999;11:359-367.
14. Martinon F, Tschopp J: NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005;26:447-454.
15. Tschopp J, Martinon F, Burns K: NALPs: A novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003;4:95-104.
16. Mariathasan S, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004;430:213-218.
17. Yamamoto M, et al. ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules. Genes Cells 2004;9:1055-1067.
18. von Moltke J, et al. Recognition of bacteria by inflammasomes. Annu Rev Immunol 2013;31:73-106.
19. Connolly DJ, Bowie AG: The emerging role of human PYHIN proteins in innate immunity: Implications for health and disease. Biochem Pharmacol 2014;92:405-414.
20. Kim YK, Shin JS, Nahm MH: NOD-like receptors in infection, immunity, and diseases. Yonsei Med J 2016;57:5-14.
21. Heneka MT, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013;493:674-678.
22. Salminen A, et al. Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology. J Cell Mol Med 2008;12:2255-2262.
23. Halle A, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 2008;9:857-865.
24. Tan MS, et al. NLRP3 polymorphisms are associated with late-onset Alzheimer's disease in Han Chinese. J Neuroimmunol 2013;265:91-95.
25. Daniels MJ, et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nat Commun 2016;7:12504.
26. Saresella M, et al. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol Neurodegener 2016;11:23.
27. Adamczak SE, et al. Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J Cereb Blood Flow Metab 2014;34:621-629.
28. Wu PJ, et al. AIM 2 inflammasomes regulate neuronal morphology and influence anxiety and memory in mice. Sci Rep 2016;6:32405.
29. Lyons MJ, et al. Clinical experience in the evaluation of 30 patients with a prior diagnosis of FG syndrome. J Med Genet 2009;46:9-13.
30. Hornung V, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009;458:514-518.
31. Fernandes-Alnemri T, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009;458:509-513.
32. Oakley H, et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 2006;26:10129-10140.
33. Chung WC, Huang TN, Hsueh YP: Targeted deletion of CASK-interacting nucleosome assembly protein causes higher locomotor and exploratory activities. Neurosignals 2011;19:128-141.
34. Lin CW, et al. Neuronally-expressed Sarm1 regulates expression of inflammatory and antiviral cytokines in brains. Innate Immun 2014;20:161-172.
35. Minami SS, et al. Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. Nat Med 2014;20:1157-1164.
36. Sunyer B, et al. Barnes maze, a useful task to assess spatial reference memory in the mice. Protocol Exch 2007 DOI: 10.1038/nprot.2007.390.
37. Hayes CD, et al. Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine. BMC Med 2013;11:81.
38. Rosen RF, et al. SDS-PAGE/immunoblot detection of Aβ multimers in human cortical tissue homogenates using antigen-epitope retrieval. J Vis Exp 2010;38:1916.
39. Liu HY, et al. TLR7 negatively regulates dendrite outgrowth through the Myd88-c-Fos-IL-6 pathway. J Neurosci 2013;33:11479-11493.
40. Jawhar S, et al. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 2012;33:196.e29-e40.
41. Tschopp J, Schroder K: NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production Nat Rev Immunol 2010;10:210-215.